Furui Co.,Ltd(SZ:300049)2022-12-06 09:46Group 1: Financial Performance - The company's overall performance in the first half of the year showed steady growth, with revenue growth outpacing profit growth due to increased R&D expenses and IPO costs [2][3]. - Medical device sales met expectations, with the U.S. market experiencing increased growth and the European market improving, while sales in China remained stable [2][3]. - Pharmaceutical sales showed moderate growth, with both sales prices and raw material costs declining [2][3]. Group 2: Market and Strategic Developments - The company has submitted its IPO application to the Hong Kong Stock Exchange and is currently under review [2][3]. - The U.S. medical device market is large, and previous sales were significantly impacted by insurance issues, which have now been resolved [3]. - The company aims to enhance its service model through deeper collaborations with hospitals, moving beyond simple partnerships [4]. Group 3: Product and Service Innovations - Echosens is focusing on continuous development in liver disease diagnostics, with plans for strategic investments to support U.S. market expansion [3][4]. - The company is upgrading its drug agency model to enhance service delivery, aiming to use profits from pharmaceuticals to drive service upgrades [4]. - The company currently has over 100 types of agency drugs, primarily sourced from manufacturers, to meet hospital demands [4]. Group 4: Insurance and Payment Models - The company plans to integrate both basic medical insurance and commercial insurance into its medical service payment models [4]. - The focus is on collaborating with local commercial companies to enhance service delivery and meet hospital needs [4]. Group 5: Future Outlook - The company anticipates that the successful IPO will provide significant support for its development in terms of funding and technology [2][3]. - There are ongoing discussions about the potential impact of the two-invoice system on sales, but currently, no negative effects have been observed [4].